This is the authors' abstract. We don't add key points for this paper.
As an emerging country, Indonesia is still in the process of implementing prophylaxis as a standard of care for managing hemophilia with limited real-world evidence in Indonesian patients. This case series details the effects of tertiary prophylaxis with an intermediate dose of factor VIII concentrate on bleeding outcomes and musculoskeletal function in three Indonesian adolescents suffering from severe haemophilia A and associated arthropathy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Primacakti et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: